Asymmetrex® is a life sciences biotechnology company with a focus on innovating adult stem cell medicine technology that will advance the potential of adult tissue stem cells into routine medical practice. Adult tissue stem cells are found in the bodies of children and adults. They are a small fraction of the cells (less than 1 per 1000) that make up organs and tissues like the liver, cornea, skin, muscles, hair, brain, and bone marrow. Despite their small fraction, they are responsible for continuously renewing and repairing the body.
Because of their normal role in maintaining and restoring organs and tissues, tissue stem cells obtained from a donating person have an inherent ability to reconstitute severely damaged tissues due to injury or disease in another recipient person. Currently, tissue stem cell transplantation treatments of this type are only available for a few tissues, e.g., bone marrow and the cornea of the eye. There are many, many more tissues in the body for which stem cell transplantation therapies are needed, but not possible. The major cause of this shortcoming – insufficient quantities of donor stem cells – often also undermines the effectiveness of the tissue stem cell treatments that are available.
Asymmetrex® holds adult stem cell patents for technologies that promote the multiplication of adult tissue stem cells. Tested so far for tissue stem cells found in the liver, lung, pancreas, muscle, skin and hair follicle, the technologies have the potential to produce therapeutic human tissue stem cells by the pound, trillions of cells at a time. Unlike other presently popularized strategies based on pluripotent stem cells, Asymmetrex’s adult stem cell medicine technology produces normal cells without high rates of mutation or tumor-forming properties. A major pursuit of Asymmetrex® is collaboration with strategic partners to develop robust manufacturing processes for producing medically important tissue stem cells and their differentiated derivative cells for use in transplantation therapies and drug development.
Another long-standing challenge in stem cell biomedicine is lack of means to identify and count tissue stem cells. Because of this need, even the available tissue stem cell therapies like bone marrow transplantation cannot be reliably optimized to achieve better treatment outcomes. This problem has existed for half a century because of the failure to discover biological markers found exclusively in or on adult tissue stem cells.
Employing its internationally recognized, special research expertise in unique adult tissue stem cell properties, Asymmetrex® recently developed its present lead technology that allows routine quantification of the specific fraction or dosage of therapeutic adult tissue stem cells. Called “kinetic stem cell (KSC) counting,” the new technology is accurate, fast, and inexpensive. This adult stem cell medicine technology and innovation provide, for the first time, the means to monitor tissue stem cell number and quality for applications in regenerative medicine and drug development. With a subscription for online calculators for rapid KSC counting, users can quickly obtain determinations of the adult tissue stem cell fraction or dosage of research, biomanufacturing, drug evaluation, and treatment samples.
By continuing to discover and develop adult stem cell medicine technology for the production, identification, and quantification of restorative adult tissue stem cells, Asymmetrex® will set the direction and pace of modern stem cell biomedicine. In addition to our current focus in developing stem cell toxicology assays for the pharmaceutical industry, we also license technologies for stem cell detection (including cancer stem cells) and stem cell expansion for user-exclusive applications.